David W. Meline - Mar 1, 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Financial Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Mar 1, 2022
Transactions value $
$0
Form type
4
Date filed
3/3/2022, 03:58 PM
Previous filing
Feb 11, 2022
Next filing
May 11, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Award $0 +26K $0.00 26K Mar 1, 2022 Common Stock 26K $149.52 Direct F1
transaction MRNA Restricted Stock Units Award $0 +6.42K $0.00 6.42K Mar 1, 2022 Common Stock 6.42K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option will vest and become exercisable on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F2 25% of the shares subject to this restricted stock unit award will vest on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.